The role of DNA repair pathways in cisplatin resistant lung cancer.
about
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectivesPreventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapyPredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells.IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated moleculesFAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancerSpheres from cervical cancer cells display stemness and cancer drug resistance.Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder.Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysisFIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposideThe novel role of pyrvinium in cancer therapy.MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer.Anti-Tumor Effects of Cardiac Glycosides on Human Lung Cancer Cells and Lung Tumorspheres.Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy.Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial CarcinomaDNA-dependent protein kinase catalytic subunit functions in metastasis and influences survival in advanced-stage laryngeal squamous cell carcinomaWhole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy.Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer.Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2.Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
P2860
Q26775315-60AE3289-677B-4990-9AD7-F0882FF44215Q28084568-1CFE55E6-476F-4B37-B2AF-B060EDC61529Q33441772-DF99BAF0-508C-4440-AB50-3E2FC96A5FB7Q33618818-7641FE00-E3EA-439D-AF76-FAF6057718ABQ33761590-2B85FB2E-30EA-4C18-BF2F-E6CE064DC486Q35766077-21A3DBC1-B8BF-486F-9287-50369026F9B0Q35847932-5EF92BB0-6FEF-449E-BC90-F815338B889EQ36413863-B6D2222B-EB68-48E8-A93D-98EFCD027D78Q37122789-6FEB1AC6-7DE5-4503-BC97-C71DAE0123E7Q37205964-78764273-8320-42C7-A953-A75B664A09B7Q37564392-88E776C8-0D8E-4094-85A6-116C338B12F1Q37687726-953DC261-CEC2-4D08-8469-9DAFFAE344F7Q37688309-F07E915E-7BBC-41DA-B52D-6A482EAA49F6Q37722114-F6B80BBE-A950-4439-BDFF-CD9BFB91C121Q38684406-C12BDAD2-EA1E-4AA7-AE2F-3CE2C57B16EFQ38734519-777E4222-E76A-48F4-A166-61208636B5C1Q38744132-7E754C42-F250-4145-89D2-A96BE13C4D43Q38848505-6A33A009-C5A7-4B7A-A2B8-07C506C964C8Q38868212-A60B89B1-3993-4307-82C8-9E8619342FC9Q41002840-772B310C-3FA9-47A9-A6AD-B9C33E8E08A9Q41441121-098E9B81-9705-4C9F-9ED4-1270C5EA5B50Q41672333-FE851FCB-36D6-4170-8FC3-1810B27A1CF6Q41718006-D943C245-C21E-40B9-95C0-5373845DB94EQ41883809-F0A241BC-C7C6-4D49-8E30-D8AC05587E71Q42292342-8896BF87-8FCC-4045-9C51-26DE9468A044Q42370438-0C074BE3-3238-44F6-9368-A87C6B155261Q47154327-0CC46A31-5924-49CA-8D27-1E1B53F916F7Q48972059-DD51BE17-936C-4DFB-BDB9-D42DC9BB777CQ49569351-6A2C9A90-C297-4F58-A59D-1D9EDE1BBC98Q52715489-A42951DE-7534-4415-8B3A-C29AED848190Q55329630-F1AE155C-9F84-4A63-A1A0-EA3C9FBEF613Q55445065-39B887AD-BD84-43BE-8B57-DACE3116D186Q57491304-8DC5D486-4268-4EE8-8360-C716479270DA
P2860
The role of DNA repair pathways in cisplatin resistant lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The role of DNA repair pathways in cisplatin resistant lung cancer.
@en
type
label
The role of DNA repair pathways in cisplatin resistant lung cancer.
@en
prefLabel
The role of DNA repair pathways in cisplatin resistant lung cancer.
@en
P50
P1476
The role of DNA repair pathways in cisplatin resistant lung cancer.
@en
P2093
Kenneth J O'Byrne
Sinead Cuffe
P304
P356
10.1016/J.CTRV.2014.10.003
P577
2014-10-18T00:00:00Z